Neuromod Devices Deepens U.S. Tinnitus Market Presence Through Clinic Partnership

According to a recent LinkedIn post from Neuromod Devices Ltd, executives Eric Timm and Holly Dean participated in an event at PEACHTREE HEARING LLC to help launch the clinic’s Tinnitus Awareness Week campaign. The post highlights Neuromod’s partnership with the Atlanta-based hearing clinic, emphasizing shared goals around tinnitus awareness, improving standards of care, and enhancing accessibility for tinnitus patients.

For investors, the activity suggests Neuromod is continuing to strengthen its clinical and referral network in the U.S. hearing-care market, particularly in a major metropolitan area. By aligning with a provider that actively promotes tinnitus education and advocacy, Neuromod may be reinforcing market adoption of its Lenire device, which the post tags as FDA-approved. Increased collaboration with specialized clinics could support higher patient throughput, improve real-world evidence for its technology, and deepen brand recognition among audiologists and patients. Over time, such partnerships may contribute to revenue growth in the U.S. tinnitus segment and bolster Neuromod’s competitive positioning within the broader hearing and neuromodulation categories.